MX349198B - Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. - Google Patents

Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.

Info

Publication number
MX349198B
MX349198B MX2014000555A MX2014000555A MX349198B MX 349198 B MX349198 B MX 349198B MX 2014000555 A MX2014000555 A MX 2014000555A MX 2014000555 A MX2014000555 A MX 2014000555A MX 349198 B MX349198 B MX 349198B
Authority
MX
Mexico
Prior art keywords
seq
rspo
join
agents
same
Prior art date
Application number
MX2014000555A
Other languages
English (en)
Spanish (es)
Other versions
MX2014000555A (es
Inventor
L Gurney Austin
Takada Axelrod Fumiko
Charles Hoey Timothy
Chartier-Courtaud Cecile
Original Assignee
Oncomed Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals Inc * filed Critical Oncomed Pharmaceuticals Inc *
Publication of MX2014000555A publication Critical patent/MX2014000555A/es
Publication of MX349198B publication Critical patent/MX349198B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
MX2014000555A 2011-07-15 2012-07-13 Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. MX349198B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161508403P 2011-07-15 2011-07-15
US201161521547P 2011-08-09 2011-08-09
US201161570629P 2011-12-14 2011-12-14
PCT/US2012/046746 WO2013012747A1 (en) 2011-07-15 2012-07-13 Rspo binding agents and uses thereof

Publications (2)

Publication Number Publication Date
MX2014000555A MX2014000555A (es) 2014-05-07
MX349198B true MX349198B (es) 2017-07-18

Family

ID=47558408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000555A MX349198B (es) 2011-07-15 2012-07-13 Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.

Country Status (14)

Country Link
US (5) US8802097B2 (https=)
EP (2) EP2731625B1 (https=)
JP (2) JP6185463B2 (https=)
KR (1) KR20140048276A (https=)
CN (2) CN106167526A (https=)
AU (1) AU2012284254B2 (https=)
BR (1) BR112014000765A2 (https=)
CA (1) CA2841745A1 (https=)
CL (1) CL2014000114A1 (https=)
IL (1) IL230429A0 (https=)
MX (1) MX349198B (https=)
RU (1) RU2014101669A (https=)
WO (1) WO2013012747A1 (https=)
ZA (1) ZA201400525B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2157192T3 (pl) 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
EP2997975A1 (en) 2006-10-20 2016-03-23 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
CN102686720B (zh) * 2009-11-17 2013-12-04 国立大学法人冈山大学 由牙髓细胞向成牙本质细胞的分化诱导方法
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
BR112014000765A2 (pt) 2011-07-15 2017-06-13 Oncomed Pharm Inc agentes de ligação a rspo e seus usos
IN2015KN00350A (https=) 2012-07-13 2015-07-10 Oncomed Pharm Inc
AU2014244444A1 (en) * 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
CN105744954B (zh) * 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
CN103724415B (zh) * 2013-12-31 2015-05-27 中山大学 斜带石斑鱼性别调控基因Rspo1及其制备方法和应用
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
CA2958144A1 (en) * 2014-08-15 2016-02-18 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
JP2017528523A (ja) * 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
MA41123A (fr) * 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2017040660A1 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
CN106913880B (zh) * 2015-12-24 2021-02-12 上海交通大学 一种含有rspo1的靶向给药系统及其制备与应用
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
CN105925576B (zh) * 2016-03-24 2018-04-20 嘉兴市第一医院 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
EP3448875A4 (en) * 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
CN118909118A (zh) * 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
CN109529040B (zh) * 2017-09-21 2020-11-13 华东师范大学 LGR4和R-spondin结合抑制剂及其在肿瘤治疗中的用途
AU2018378668B2 (en) * 2017-12-07 2025-04-10 National Health Research Institutes Anti-RSPO3 antibodies
CN110339364B (zh) * 2018-04-02 2021-02-12 上海邦耀生物科技有限公司 Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗
KR20210007959A (ko) 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
US12497464B1 (en) 2018-08-03 2025-12-16 Berkeley Therapeutics, Inc. Antibody, antibody fragments or peptide for treating cancer and methods of formation and administration
GB201901710D0 (en) * 2019-02-07 2019-03-27 Nordic Bioscience As Collagen type 23 assay
CN110467663B (zh) * 2019-06-18 2022-05-10 华南农业大学 Rspo3基因在母猪卵巢颗粒细胞中的应用
US20220267735A1 (en) * 2019-08-05 2022-08-25 Genex Health Co., Ltd Method for culturing primary cells from solid tumor of lung cancer and primary tumor cells from pleural effusion of lung cancer and auxiliary reagents
WO2021070181A1 (en) 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
US20230338466A1 (en) * 2020-06-03 2023-10-26 Children's Hospital Medical Center Compositions and methods comprising r-spondins for treatment of tumors
CN112457400B (zh) * 2020-12-09 2022-03-08 福州迈新生物技术开发有限公司 抗β-catenin蛋白单克隆抗体、细胞系及其制备方法和应用
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
CN116239680B (zh) * 2023-02-09 2024-02-06 义翘神州(泰州)科技有限公司 猴痘病毒a29小鼠单克隆包被抗体及检测抗体
KR102554222B1 (ko) * 2023-03-21 2023-07-11 순천향대학교 산학협력단 신규한 항-인간 알스폰딘3 항체 및 이의 용도
KR102551095B1 (ko) * 2023-03-21 2023-07-04 순천향대학교 산학협력단 신규한 항-인간 알스폰딘2 항체 및 이의 용도

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US20070124581A1 (en) 1992-05-17 2007-05-31 Reena Khare Cell adhesion and extracellular matrix proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
JP2001527403A (ja) 1997-04-25 2001-12-25 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
EP1017811A4 (en) 1997-09-24 2002-08-14 Merck & Co Inc HG38 GLYCOPROTEIN HORMONE RECEPTOR COUPLED WITH G-PROTEIN
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
DE69941330D1 (de) 1998-03-26 2009-10-08 Univ R Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
US20030166047A1 (en) 1999-05-06 2003-09-04 Millennium Pharmaceuticals, Inc. Lgr6 nucleic acids and uses thereof
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001074164A1 (en) 2000-03-31 2001-10-11 The General Hospital Corporation Methods of modulating hair growth
AU5904101A (en) 2000-04-05 2001-10-23 Hyseq Inc Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030139341A1 (en) 2000-05-30 2003-07-24 Shyam Ramakrishnan Regulation of human lgr4-like g protein -coupled receptor
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US6768004B2 (en) 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
US20030032034A1 (en) 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20100292155A1 (en) 2001-03-05 2010-11-18 Arca Biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
EP1395610A2 (en) 2001-06-11 2004-03-10 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
CA2458818A1 (en) 2001-08-30 2003-04-10 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
EP1434796A2 (en) 2001-10-03 2004-07-07 Incyte Genomics, Inc. Secreted proteins
US20040197778A1 (en) 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
CA2469204A1 (en) 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
EP1504099A4 (en) 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7439332B2 (en) 2002-04-26 2008-10-21 Kirin Pharma Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004074436A2 (en) 2003-02-19 2004-09-02 Incyte Corporation Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20050054829A1 (en) 2003-07-22 2005-03-10 Wiley Steven R. Compositions and methods relating to TSP-30a, b, c and d
DE10339820A1 (de) 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
PL2157192T3 (pl) 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
WO2005040828A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1727560B1 (en) 2004-01-27 2012-09-12 Kyowa Hakko Kirin Co., Ltd. Gastrointestinal proliferative factor and uses thereof
AU2005209909B8 (en) 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
US20090036369A1 (en) 2005-07-26 2009-02-05 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
US7541431B2 (en) 2005-09-07 2009-06-02 Maine Medical Center Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
WO2007100357A2 (en) 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
AR061170A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
JP2008044926A (ja) 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
SG174100A1 (en) 2006-09-08 2011-09-29 Genentech Inc Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
EP2997975A1 (en) * 2006-10-20 2016-03-23 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
WO2008075796A1 (ja) 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. 血球回復促進剤
WO2008088524A2 (en) 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008156713A2 (en) 2007-06-12 2008-12-24 Wyeth Anti-cd20 therapeutic compositions and methods
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
US20100285001A1 (en) 2007-10-02 2010-11-11 University Of Rochester Method and Compositions Related to Synergistic Responses to Oncogenic Mutations
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
WO2009063970A1 (ja) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
KR101682257B1 (ko) 2008-10-31 2016-12-05 도레이 카부시키가이샤 인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법
WO2010121923A1 (en) 2009-04-15 2010-10-28 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
WO2010129284A1 (en) 2009-04-27 2010-11-11 The Trustees Of The University Of Pennsylvania Inhibition of hair follicle growth by the wnt inhibitor dkk1
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2011009090A1 (en) 2009-07-16 2011-01-20 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
EP2977060A1 (en) 2009-12-23 2016-01-27 Deutsches Krebsforschungszentrum Receptors of rspo2 and rspo3
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2786745A1 (en) 2010-01-12 2011-07-21 Oncomed Pharmaceuticals, Inc. Wnt-binding agents and uses thereof
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
AU2011352167A1 (en) 2010-12-28 2013-07-11 Caris Mpi, Inc. Molecular profiling for cancer
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
EP2702412B1 (en) 2011-04-28 2017-07-26 SBI Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase antibody
BR112014000765A2 (pt) 2011-07-15 2017-06-13 Oncomed Pharm Inc agentes de ligação a rspo e seus usos
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
IN2015KN00350A (https=) 2012-07-13 2015-07-10 Oncomed Pharm Inc
CN105142641A (zh) 2013-03-12 2015-12-09 广州源生医药科技有限公司 用于治疗癌症的化合物
WO2014192974A1 (ja) 2013-05-30 2014-12-04 株式会社オーダーメードメディカルリサーチ 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬
CN105744954B (zh) 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer

Also Published As

Publication number Publication date
MX2014000555A (es) 2014-05-07
EP2731625A4 (en) 2015-02-25
EP2731625B1 (en) 2018-04-18
US9109024B2 (en) 2015-08-18
CN106167526A (zh) 2016-11-30
US9109025B2 (en) 2015-08-18
US20150010571A1 (en) 2015-01-08
US9644034B2 (en) 2017-05-09
US20150010565A1 (en) 2015-01-08
RU2014101669A (ru) 2015-09-20
ZA201400525B (en) 2015-05-27
EP3401329A1 (en) 2018-11-14
JP2014524746A (ja) 2014-09-25
JP6185463B2 (ja) 2017-08-23
WO2013012747A1 (en) 2013-01-24
US8802097B2 (en) 2014-08-12
CN104023746A (zh) 2014-09-03
AU2012284254B2 (en) 2015-07-09
US20160002344A1 (en) 2016-01-07
CL2014000114A1 (es) 2014-08-18
US20130095116A1 (en) 2013-04-18
CA2841745A1 (en) 2013-01-24
NZ620100A (en) 2016-06-24
CN104023746B (zh) 2016-08-17
AU2012284254A1 (en) 2013-03-14
US20170298143A1 (en) 2017-10-19
BR112014000765A2 (pt) 2017-06-13
EP2731625A1 (en) 2014-05-21
JP2017169578A (ja) 2017-09-28
KR20140048276A (ko) 2014-04-23
IL230429A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
CL2018003583A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos.
PE20160553A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
CY1121158T1 (el) Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20142322A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
PE20131209A1 (es) Anticuerpos anti-fap
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20142407A1 (es) Formulacion de anticuerpos
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20140247A1 (es) Anticuerpos anti-cd38
GT201400045A (es) Anticuerpo anti-abtcr
MX354101B (es) FORMULACION PARA ANTICUERPO ANTI -A4ß7.
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph

Legal Events

Date Code Title Description
FG Grant or registration